C2N and Unilabs team up on brain health diagnostics

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Partnership aims to bring C2N’s portfolio of Alzheimer’s blood testing products to more than 75 countries.

Alzheimer’s blood test developer C2N Diagnostics has signed a partnership with European diagnostic services giant Unilabs, which plans to offer the US-firm’s portfolio of blood tests in more than 75 countries around the world. The multi-year agreement gives Unilabs exclusive access to C2N’s Precivity blood tests across key regions in Europe, the Gulf Region and Latin America.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3080

C2N Diagnostics

Longevity level(s):

  • Level 4: Longevity clinical services
    Professionally qualified clinics that offer diagnosis of health and aging biomarkers; clinical guidance on lifestyle, diet and therapeutic interventions to mitigate the progression of age.

Overview

C2N Diagnostics is a specialty diagnostics company focused on developing and commercializing blood-based biomarker tests for the early detection and monitoring of Alzheimer's disease and related neurodegenerative disorders. The company leverages proprietary high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies to identify and quantify protein biomarkers implicated in neurological disease pathology. C2N's flagship products, the PrecivityAD® and PrecivityAD2™ blood tests, measure amyloid pathology and tau-related biomarkers to aid in clinical diagnosis, treatment monitoring, and clinical trial enrollment. The company's mission centers on transforming neurodegenerative disease diagnosis through precision medicine approaches that provide accessible, minimally invasive alternatives to invasive imaging and cerebrospinal fluid testing.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE